Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04637620 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NMDA Modulation in Major Depressive Disorder

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 2024 to Nov 2026
    • Study completion date: Dec 2024 to Dec 2026
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Primary completion date: Sep 2022 to Sep 2024
    • Study completion date: Dec 2022 to Dec 2024
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
Trial Details
NCT Number NCT04637620
Lead Sponsor China Medical University Hospital
Collaborators: Ministry of Science and Technology, Taiwan
Conditions
(from sponsor)		 Major Depressive Disorder
Related terms Major Depressive Disorder
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov